Ask AI
ProCE Banner Activity

gMG C5 Inhibitors: Matching Therapy to Patient Needs

Podcast Episodes

Srikanth Muppidi, MD; Pushpa Narayanaswami, MD, FAAN; Henry J. Kaminski, MD; and Pritikanta Paul, MD, discuss persistent needs in generalized myasthenia gravis and practical differentiation of gMG C5 inhibitors. They review treatment burden, access barriers, infection risk mitigation, route and frequency of administration, patient preferences, and individualized treatment planning.

Released: June 30, 2026

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc

Target Audience

This activity is intended for neurologists, neuromuscular specialists, advanced practice providers, nurses, and pharmacists caring for patients with MG.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Summarize the unmet medical needs in the care of people living with MG, including those who do not adequately respond to first-line therapies

  • Differentiate novel C5 inhibitors based on their clinical characteristics, such as efficacy, safety profiles, and schedules/routes of administration

  • Design individualized care plans for people with gMG that integrate evidence-based use of C5 inhibitors, considering mechanism of action, efficacy, safety, and evolving clinical roles in order to support long-term adherence and improved quality of life

Financial Disclosures

Primary Author

Henry J. Kaminski, MD: consultant/advisor/speaker: Canopy Immunotherapeutics, EMD Serono, Novartis, UCB Pharma; researcher: Merck, Mimivax, UCB Pharma.

Srikanth Muppidi, MD: consultant/advisor/speaker: Alexion/AstraZeneca, Amgen, Johnson & Johnson, Kyverna.

Pushpa Narayanaswami, MD, FAAN: researcher: Alexion, Argenx, Cabaletta Bio, Dianthus; consultant/advisor/speaker: Alexion, Amgen, Cartesian, Dianthus, EMD Serono, Johnson & Johnson, Regeneron, UCB, Vor Bio; other financial or material support: Alexion, Argenx, Dianthus, UCB; data and safety monitoring board: Alexion, Johnson & Johnson, NMD Pharma, Sanofi, UCB.